Ozempic vs. Wegovy: same ingredient, different approvals
Both Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist. The difference is what each one is FDA-approved for:
| | Ozempic | Wegovy | |---|---|---| | Approved use | Type 2 diabetes (blood sugar control, cardiovascular risk reduction) | Chronic weight management (and cardiovascular risk reduction in certain adults) | | Max weekly dose | 2 mg | 2.4 mg |
In the STEP 1 clinical trial, adults without diabetes taking semaglutide 2.4 mg weekly lost about 15% of body weight on average over 68 weeks, compared with about 2% on placebo, alongside lifestyle changes. Individual results vary.
Who qualifies for a weight-management prescription?
Wegovy's labeling for weight management covers adults with:
- a BMI of 30 or higher, or
- a BMI of 27 or higher with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol).
A provider will also check for reasons it may not be safe — for example a personal or family history of medullary thyroid cancer or MEN 2, a history of pancreatitis, or pregnancy.
Step-by-step: getting a prescription
- Get evaluated by a licensed provider — your primary care doctor, an obesity-medicine specialist, or a telehealth provider licensed in your state.
- Share your health history, current medications and BMI. Labs may be requested.
- Discuss options. Depending on your history, your provider may recommend semaglutide, tirzepatide, another medication, or no medication.
- Check coverage and cost. Many insurance plans don't cover medication for weight loss; cash-pay prices vary by product.
- Start low, go slow. Doses are increased gradually to reduce side effects like nausea.
Insurance coverage and prior authorization
Coverage is the biggest practical hurdle. Plans may cover Ozempic for type 2 diabetes but exclude Wegovy for weight management, or cover it only after prior authorization. A prior authorization request typically includes:
- your BMI and weight history;
- weight-related conditions such as high blood pressure or type 2 diabetes;
- previous attempts at weight loss, such as structured diet programs;
- confirmation that the medication is being used for an approved indication.
Medicare Part D generally cannot cover drugs used only for weight loss, although some brand-name products may be covered for other FDA-approved uses, such as reducing cardiovascular risk in eligible adults. Check your plan's formulary or call the number on your card for specifics.
Why off-label use of Ozempic for weight loss is discouraged
Ozempic is approved for type 2 diabetes. Some prescribers use it off-label for weight loss, but insurance often will not cover it for that use, and supply for people with diabetes can be affected. When the goal is weight management, providers usually choose a product or program intended for that purpose.
Other options your provider may discuss
- Tirzepatide, the active ingredient in Zepbound and Mounjaro, which acts on both GLP-1 and GIP receptors;
- Compounded semaglutide or tirzepatide from licensed pharmacies, which are not FDA-approved;
- Other FDA-approved weight-management medications with different mechanisms;
- Lifestyle-focused programs and treatment of related conditions when medication is not appropriate.
Compare semaglutide and tirzepatide.
Safety first: who should not take a GLP-1
GLP-1 medications are not right for everyone. A provider will generally not prescribe semaglutide or tirzepatide if you are pregnant, planning a pregnancy or breastfeeding, or if you have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN 2). A history of pancreatitis, gallbladder disease, severe digestive conditions such as gastroparesis, kidney problems, diabetic eye disease or an eating disorder also needs careful review. Be completely honest on your assessment, including supplements and medications prescribed by other doctors, because insulin and sulfonylureas can raise the risk of low blood sugar when combined with a GLP-1.
Telehealth as an option
Because GLP-1 medications are not controlled substances, a licensed provider can prescribe them after an online evaluation. At EdenRx, patients in Florida and New York complete a free assessment; our medical team under Dr. Jean-Yves Dastain, MD reviews it, usually within 24–48 hours, and you only pay if you're approved.
EdenRx programs use compounded semaglutide and compounded tirzepatide prepared by licensed U.S. pharmacies. Compounded medications are not FDA-approved and are not the same as Ozempic, Wegovy, Mounjaro or Zepbound. See current pricing and how semaglutide works.
What to bring to your appointment
- Your height, a recent weight and, if possible, waist measurement;
- A list of all medications and supplements;
- Recent lab results;
- Your insurance card and pharmacy information;
- Notes on past weight-loss attempts and what happened;
- Your questions about side effects, timelines and cost.
Questions to ask before you start
- Is this medication appropriate with my other conditions and medications?
- What side effects should I expect, and when should I call you?
- How will my dose be adjusted?
- What happens if I stop?
This article is for education only and is not medical advice. Results vary.






























